Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Major Depressive Disorder: full-pipeline trial registry
109 of 283 indexed Major Depressive Disorder trials are currently recruiting.
Corpus placement: #33 of 28,707 conditions by registered trial count.
283 US clinical trials · 109 currently recruiting · #33 of 28,707 conditions by registered trial count
Major Depressive Disorder: 283 US clinical trials tracked, 109 recruiting.
Major Depressive Disorder is the subject of 283 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 74 are in Phase 3-4 (later-stage) and 81 in Phase 1-2 (earlier-stage). The most active sponsor is Massachusetts General Hospital, running 19 of these trials.
Enrollment posture brief
Registry condition major-depressive-disorder
OPEN 109 | RECR 39% | LATE 74 | EARLY 81 | RANK #33 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Anaplastic Oligodendroglioma (38% recruiting · 13 trials)
Major Depressive Disorder lists 109 open slots (39% of 283 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Major Depressive Disorder on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Major Depressive Disorder recruits in line with its size-band peers.
109 of 283 indexed trials (38.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Major Depressive Disorder trials is spread across many organizations.
Massachusetts General Hospital accounts for 19 of 283 trials (6.7%). 118 distinct sponsors appear on at least one study for this condition label.
-
Typical Major Depressive Disorder enrolment sits around 81 participants.
Median target enrolment is 81 among the 283 trials that report a genuine target (sentinel values excluded). 145 of those (51.2%) plan for fewer than 100 participants.
-
Major Depressive Disorder research is mostly interventional.
258 interventional and 25 observational studies make up this index (91.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
283 total, page 1 of 6
RIVER At Home Ketamine Protocols
RIVER Foundation
NCT06070766
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
National Institute of Mental Health (NIMH)
NCT00018057
Study to Assess the Safety and Effectiveness of NMRA-335140-501
Neumora Therapeutics
NCT06029439
University of Iowa Interventional Psychiatry Service Patient Registry
Mark Niciu
NCT04480918
Defining Neurobiological Links Between Substance Use and Mental Illness
National Institute on Drug Abuse (NIDA)
NCT05538910
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
Massachusetts General Hospital
NCT04296604
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
NCT06966401
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
NCT07196501
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Intra-Cellular Therapies
NCT05850689
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
Sirtsei Pharmaceuticals
NCT06254612
MicroRNA Correlates of Childhood Maltreatment and Suicidality
University of Alabama at Birmingham
NCT04923685
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Xenon Pharmaceuticals
NCT06775379
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Xenon Pharmaceuticals
NCT07076407
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
Axsome Therapeutics
NCT06223880
Biomarker-guided rTMS for Treatment Resistant Depression
Weill Medical College of Cornell University
NCT04041479
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
Neumora Therapeutics
NCT06058013
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
Neumora Therapeutics
NCT06058039
Study of ALTO-300 in MDD
Alto Neuroscience
NCT05922878
Taking Action for College Students
Temple University
NCT06700902
Regulation of Affect and Physiology in Depression
University of Southern California
NCT06345859
Sensory Synchronized Imaging and Neuromodulation
VA Office of Research and Development
NCT06548113
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
University of Alabama at Birmingham
NCT05437588
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics
NCT06633016
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
Mclean Hospital
NCT05630963
Clinical Validation of Samsung Smartwatch
Massachusetts General Hospital
NCT05767593
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Cybin IRL Limited
NCT06564818
Combination of Novel Therapies for CKD Comorbid Depression
Stony Brook University
NCT04422652
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
Kymberly Young
NCT05703256
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
NCT06786624
RESISTance Exercise for Depression Trial
University of Wisconsin, Madison
NCT06110897
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
NCT06911112
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
NCT06963021
IPT for Major Depression Following Perinatal Loss: Healing After Loss (HeAL)
Michigan State University
NCT04629599
Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study
Mayo Clinic
NCT06897670
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
AbbVie
NCT07276997
Mechanisms of Rumination Change in Adolescent Depression
Ohio State University
NCT03859297
Neural Response to Inflammatory Challenge in Major Depressive Disorder
Laureate Institute for Brain Research
NCT04751331
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
Brigham and Women's Hospital
NCT06376734
Antidepressant Effects of Nitrous Oxide
University of Chicago
NCT05357040
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences
NCT07115329
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Syndeio Biosciences
NCT06547489
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
National Institute of Mental Health (NIMH)
NCT03065335
Reward Processing and Depressive Subtypes: Identifying Neural Biotypes
San Francisco Veterans Affairs Medical Center
NCT06080646
Stress Dynamics and Familial Risk for Depression in Female Adolescents
Mclean Hospital
NCT06816329
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
University of Illinois at Chicago
NCT05051618
Optimizing Brain Excitability in Depression
Stanford University
NCT07242105
Evaluating tDCS Brain-stimulation in Depression Using MRI
University of California, Los Angeles
NCT05598034
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Emory University
NCT05327699
Positive Processes and Transition to Health (PATH)
Case Western Reserve University
NCT06093906
Imaging SV2A in Mood Disorders
Yale University
NCT02734602
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 24 |
| Phase 2 | 57 |
| Phase 3 | 45 |
| Phase 4 | 29 |
Top Sponsors
Named interventions
Most-linked intervention names on Major Depressive Disorder records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Major Depressive Disorder trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Major Depressive Disorder page
283 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 109 Major Depressive Disorder trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Massachusetts General Hospital sponsors the most Major Depressive Disorder trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Major Depressive Disorder condition card totals 283 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.